To include your compound in the COVID-19 Resource Center, submit it here.

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

The deal, which includes an anti-TIGIT mAb, resembles Gilead’s relationship with Galapagos, albeit on smaller scale

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty Seven Inc. grew into a buyout, so much as its long-term ties with Galapagos, albeit on a smaller scale.

Gilead Sciences Inc. (NASDAQ:GILD) will pay Arcus Biosciences Inc. (NASDAQ:RCUS) $175 million up front and make a $200 million equity investment in the biotech, gaining exclusive rights immediately

Read the full 814 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers